# COVID-19 Vaccines Linked to Lower Risk of Heart Failure and Blood Clots, Major Study Finds
## International research involving more than 20 million people highlights the potential cardiovascular benefits of COVID-19 vaccination
COVID-19 vaccination may offer benefits that extend beyond reducing the severity of respiratory illness. A large international study has found that vaccinated people who subsequently developed COVID-19 faced a lower risk of several serious cardiovascular complications, including heart failure and blood clots, than unvaccinated people who contracted the virus.
The findings, published in the medical journal *Heart* in 2024, add to the growing body of research examining how vaccination may influence the health consequences of SARS-CoV-2 infection. Researchers analyzed health records from more than 20 million people across the United Kingdom, Spain, and Estonia, comparing the risk of cardiovascular and clotting complications following COVID-19 among vaccinated and unvaccinated individuals.
The results suggested that vaccination was associated with a substantial reduction in these complications, particularly during the first month after infection. Although the protective association became less pronounced over time, lower risks were observed for certain conditions for as long as a year after COVID-19.
The findings are significant because the effects of COVID-19 are not limited to the lungs. Infection can affect multiple systems throughout the body, and cardiovascular complications have been an important concern for doctors and researchers since the beginning of the pandemic.
However, the study also highlights the importance of interpreting medical evidence carefully. The research was observational, meaning it identified associations in health records rather than proving that vaccination alone caused every difference in outcomes. Even so, its size and multinational scope provide valuable evidence about the relationship between COVID-19 vaccination and cardiovascular health.
## A study involving more than 20 million people
To investigate the relationship between vaccination and cardiovascular complications, researchers examined electronic health records from several large healthcare databases in the UK, Spain, and Estonia.
The study included approximately 10.17 million vaccinated people and 10.39 million unvaccinated people. Researchers evaluated the occurrence of complications after COVID-19 infection, focusing on heart failure, venous thromboembolism, and arterial thrombosis or thromboembolism.
These conditions can have serious consequences. Blood clots may obstruct circulation in veins or arteries, while heart failure occurs when the heart cannot pump blood effectively enough to meet the body's needs.
The research examined outcomes during several periods following infection, including the first 30 days and later intervals extending to one year.
By analyzing such a large population across different countries, the investigators could examine whether the relationship between vaccination and cardiovascular outcomes appeared consistently across different healthcare systems and populations.
The researchers also used statistical methods designed to account for differences between vaccinated and unvaccinated individuals. These adjustments can help reduce the influence of factors that might otherwise distort comparisons.
Nevertheless, no observational study can eliminate every possible source of bias. Differences in health status, healthcare access, infection history, and other factors may still influence the results.
The findings should therefore be understood as strong population-level evidence of an association, rather than a guarantee that every vaccinated person will be protected from cardiovascular disease.
## What did the researchers discover?
The study found that vaccination was associated with lower risks of heart failure and both venous and arterial clotting complications after COVID-19 infection.
The difference was particularly pronounced during the first 30 days following infection, when cardiovascular and clotting complications may be especially concerning.
During this period, the researchers reported approximately:
- **78% lower relative risk of venous blood clots**, based on the study's statistical estimate.
- **47% lower relative risk of arterial clotting complications.**
- **55% lower relative risk of heart failure.**
These figures describe relative reductions in risk, not the percentage of all vaccinated people who would otherwise develop these conditions. They also do not mean that vaccination eliminates the possibility of a blood clot or heart failure.
For example, a relative reduction of 55% means that the estimated risk was lower by that proportion compared with the reference group. The actual benefit for an individual depends on their underlying risk, age, medical history, and other circumstances.
The researchers also found that lower risks of several complications persisted beyond the first month. In some analyses, the association remained evident between six months and one year after infection.
This longer-term finding is important because COVID-19 can have consequences that continue after the initial infection has passed. Some people experience ongoing symptoms or develop health problems in the weeks and months following illness.
The results suggest that reducing the severity and consequences of the initial infection may have benefits that extend beyond the acute phase.
## Why can COVID-19 affect the heart and blood vessels?
COVID-19 is primarily recognized as a respiratory disease, but its effects can extend well beyond the respiratory system.
During infection, the body's immune response can trigger inflammation. In some people, this inflammatory response can affect blood vessels, influence normal clotting processes, and place additional strain on the cardiovascular system.
Blood clots are particularly concerning because they can interfere with the delivery of oxygen-rich blood to vital organs.
A clot in a deep vein, often in the leg, may cause deep vein thrombosis. If part of that clot travels to the lungs, it can cause a pulmonary embolism, a potentially life-threatening emergency.
Arterial clots involve blood vessels that carry blood away from the heart. Depending on their location, they may contribute to conditions such as heart attacks or ischemic strokes.
COVID-19 can also place stress on the heart through inflammation, reduced oxygen levels, and other complications associated with serious illness.
In some cases, these effects may contribute to heart failure or worsen existing cardiovascular disease.
Not everyone who develops COVID-19 experiences these complications. The likelihood depends on factors such as the severity of infection, age, pre-existing conditions, and other individual characteristics.
Nevertheless, the potential for cardiovascular complications helps explain why researchers have examined whether preventing severe COVID-19 might also reduce the risk of heart and blood-vessel problems.
## How might vaccination reduce these risks?
COVID-19 vaccines are designed to prepare the immune system to recognize the virus and respond more effectively when exposure occurs.
Vaccination does not guarantee that a person will never become infected. Breakthrough infections can occur, particularly as the virus evolves and immune protection against infection changes over time.
However, vaccination can reduce the risk of severe illness. If an infection is less likely to become severe, the body may be less likely to experience some of the intense inflammatory and physiological disturbances associated with serious COVID-19.
This offers a plausible explanation for the lower cardiovascular risks observed in vaccinated people.
The researchers suggested that the protective association was likely related, at least in part, to vaccination's ability to reduce the risk and severity of COVID-19.
In other words, vaccination may help protect the cardiovascular system indirectly by reducing the likelihood of severe infection and its downstream complications.
This does not mean that vaccines act as direct treatments for heart failure or blood clots. Nor does it mean that vaccination replaces medication, screening, or other care for people with cardiovascular conditions.
Instead, the findings suggest that preventing or reducing the severity of an infection may help reduce some of the health problems that can follow it.
## Did the protection last for a year?
One of the notable findings was that lower risks of certain cardiovascular and clotting complications remained associated with vaccination well beyond the initial infection.
The study found evidence of reduced risks during later follow-up periods, including intervals extending to 12 months.
However, the magnitude of the association varied depending on the condition and the time since infection. Protection was generally strongest in the acute period and less pronounced during later periods.
This distinction is important. It would be inaccurate to interpret the findings as meaning that every vaccinated person receives the same level of protection for a full year.
Immune responses vary between individuals, and protection can be influenced by the type of vaccine received, the number and timing of doses, previous infections, and the circulating viral variant.
The study also does not establish that every booster dose produces the same cardiovascular benefit or that protection remains unchanged over time.
Further research is needed to clarify how different vaccination schedules, updated vaccines, and subsequent infections influence long-term cardiovascular outcomes.
Even with these limitations, the findings suggest that the relationship between vaccination and cardiovascular health may extend beyond the immediate prevention of severe respiratory disease.
## What about reports of vaccine-related heart problems and blood clots?
Any discussion of cardiovascular health and COVID-19 vaccination should acknowledge that rare adverse events have been identified with certain vaccines.
For example, myocarditis and pericarditis—inflammation of the heart muscle and the tissue surrounding the heart—have been associated with some mRNA COVID-19 vaccines, particularly in certain younger male age groups.
Rare clotting disorders have also been associated with particular adenovirus-vector vaccines.
These risks differ according to the vaccine, the person's age and sex, and other relevant factors. They should be considered using evidence specific to the vaccine and population involved.
The multinational study does not mean that vaccine-related adverse events never occur. Instead, it examined the overall risk of selected cardiovascular and clotting complications following COVID-19 infection among vaccinated and unvaccinated groups.
These are related but distinct questions.
An individual may experience a medical problem after vaccination, but the timing alone cannot establish that vaccination caused it. Likewise, the existence of a rare adverse event does not automatically tell us what the overall balance of benefits and risks is for every population.
Researchers assess these questions through multiple sources of evidence, including clinical trials, safety-monitoring systems, medical records, and studies comparing outcomes across large populations.
The most useful approach is to recognize genuine risks while evaluating them alongside the risks of COVID-19 itself.
## Why the findings matter for people with existing heart conditions
People with pre-existing cardiovascular disease may be particularly concerned about COVID-19 because serious infections can place additional strain on the heart and circulation.
For someone living with heart failure, coronary artery disease, or another chronic cardiovascular condition, a severe respiratory infection may complicate an already challenging medical situation.
The study's findings may therefore be relevant to understanding the broader potential benefits of preventing severe COVID-19 in people who face elevated cardiovascular risks.
However, the research should not be interpreted as a personalized prediction. It does not establish the exact amount of protection any individual will receive, nor does it mean that vaccination alone can prevent a heart attack, blood clot, or worsening heart failure.
People with existing heart conditions should continue following their treatment plans, attending recommended medical appointments, and discussing vaccination with their healthcare professionals.
A clinician can consider an individual's medical history, current health, previous vaccine reactions, and local recommendations when providing advice.
## Important limitations of the research
Although the study's size is a major strength, several limitations should be considered.
First, the researchers relied on observational health records rather than randomly assigning people to vaccination groups. As a result, the study can identify associations but cannot establish cause and effect with the same certainty as a well-designed randomized trial.
Second, vaccinated and unvaccinated people may differ in important ways. Researchers used statistical adjustments to make the groups more comparable, but unmeasured differences may still have influenced the findings.
Third, the results reflect particular populations, healthcare systems, vaccines, and periods of the pandemic. The relationship between vaccination and complications may change as new variants emerge, population immunity changes, and vaccination recommendations evolve.
Finally, the study focused on specified cardiovascular and clotting outcomes after infection. Its results should not be extended automatically to every heart condition, every possible vaccine side effect, or every individual.
These limitations do not make the findings unimportant. Rather, they help define what the study can—and cannot—tell us.
When large observational studies produce consistent results across several countries, they can provide valuable evidence to guide further research and public-health decisions.
## Recognizing the warning signs of cardiovascular complications
Regardless of vaccination status, people should take possible symptoms of serious cardiovascular problems seriously.
Symptoms that may indicate a blood clot or another urgent medical condition include sudden difficulty breathing, chest pain, coughing up blood, or one-sided leg swelling accompanied by pain.
Possible signs of a heart attack include chest pressure or discomfort, shortness of breath, sweating, nausea, or pain spreading to the arm, back, neck, or jaw. A stroke may cause sudden facial drooping, weakness in an arm or leg, or difficulty speaking.
These symptoms can have several causes, but they warrant urgent medical assessment. Severe or sudden symptoms should not be ignored while someone tries to determine whether they are connected to COVID-19 or vaccination.
People recovering from COVID-19 who develop new or worsening symptoms should contact a healthcare professional for appropriate evaluation.
Vaccination does not remove the need for medical care, and no preventive measure offers complete protection against every possible illness.
## Conclusion: A broader understanding of COVID-19 prevention
The international study involving more than 20 million people provides evidence that COVID-19 vaccination was associated with lower risks of heart failure, venous blood clots, and arterial clotting complications following infection.
The strongest associations were observed during the first month after COVID-19, although lower risks for certain outcomes remained evident during later follow-up periods.
These findings reinforce the importance of considering COVID-19 as more than a respiratory illness. Its effects can extend to the heart and blood vessels, and complications may continue after the initial infection.
At the same time, the results should be interpreted carefully. The study was observational, individual protection varies, and rare vaccine-related adverse events remain an important part of vaccine-safety monitoring.
The central message is not that vaccination guarantees cardiovascular health or eliminates every risk. It is that preventing severe COVID-19 may also help reduce the risk of serious complications affecting the heart and circulation.
For individuals considering vaccination, the best decision depends on their personal health circumstances and current public-health recommendations. Consulting a qualified healthcare professional can help clarify the benefits, risks, and options that are most appropriate for each person.
As researchers continue studying the long-term consequences of COVID-19, evidence of this kind helps build a more complete picture of how vaccination may contribute to protecting health beyond the initial infection.
